FXIa inhibition in non-cardioembolic stroke patients

FXIa inhibition in noncardioembolic stroke patients
3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD
  • Overview

    ESC 2022 Ashkan Shoamanesh gives a summary of the primary results and exploratory analyses of the phase 2 PACIFIC-STROKE trial with asundexian in patients with non-cardioembolic stroke.

  • Educational information

    This video was recorded during the ESC Congress 2022 in Barcelona, Spain.

  • Faculty

    Ashkan Shoamanesh is the Director of the Hemorrhagic Stroke Research Program at the Population Health Research Institute at Hamilton Health Sciences, Hamilton, Canada.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the PACIFIC-STROKE

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free